Skip to main content

Eyal Peled represents domestic and international clients in a broad range of corporate transactions. His work includes advising clients as part of their capital raising, financings, mergers and acquisitions, and other securities and transactional matters. In addition, Eyal supports clients in a wide range of industries with their day-to-day and strategic legal needs.

As part of his securities-related experience, Eyal has advised companies and underwriters on a wide range of topics, including SEC filings, public company reporting and other compliance/disclosure requirements, and provides counsel on private placements, initial public offerings (IPOs), and token offerings.

Prior to joining Greenberg Traurig, Eyal worked at other large U.S. law firms representing major U.S. companies and private equity funds. He also has deep cross-border experience, having worked as a U.S. lawyer in London for three years.

Concentrations

  • Public and private securities offerings, including private company representation from formation to IPO
  • Venture Capital transactions
  • Blockchain and AI technologies
  • Pharma, medical device, digital health and other life sciences
  • Israel practice

Capabilities

Recognition & Leadership

  • BDICode (Israel)
    • Capital Markets, Prominent Leaders, 2024
  • Chambers Global, Corporate/M&A: International Firms (Expertise Based Abroad), Team Member, 2022-2024
  • Dun's 100 (Israel)
    • Recognized, International Commercial, Prominent Team, 2022-2024
    • Recognized, Hi-Tech, Notable Law Firm, 2022-2024
  • LegallyIsrael100
    • Recognized, M&A, 2022-2024
    • Recognized, Hi-Tech, 2022-2024
    • Recognized, Litigation, 2022-2024
    • Recognized, Capital Markets, 2022-2024
    • Recognized, Banking & Finance, 2022-2024

Credentials

Education
  • LL.M., University of Chicago Law School, 2014
  • LL.B., cum laude, University of Haifa, 2012
  • B.A., Economics, University of Haifa, 2012
Admissions
  • New York
Languages
  • Hebrew

Related Capabilities

Corporate Capital Markets Mergers & Acquisitions Life Sciences & Medical Technology Blockchain & Digital Assets Venture Capital & Emerging Technology Fintech